We recently found that a small molecule 2 [[3-(2,3-dichlorophenoxy)propyl]amino]ethanol (2,3-DCPE) could induce apoptosis and downregulate Bcl-XL expression in various cancer cells. Here, we found that 2,3-DCPE suppressed the proliferation of Bcl-XL-overexpressing cancer cells without inducing apoptosis. Subsequently, we found that 2,3-DCPE could induce S-phase arrest and upregulate p21 but not p27 at a time-and dose-dependent but p53-dispensable manner in DLD-1 human colon cancer cells. Activation of ERK was also detected after treatment with 2,3-DCPE. Moreover, p21 induction was dramatically attenuated by ERK inhibitors PD98059 and U0126. Induction of p21 and S-phase arrest and corresponding activation of ERK were also observed in ATM-defective cells, suggesting that 2,3-DCPE-induced these events were ATM-dispensable. Furthermore, ERK inhibitors dramatically attenuated 2,3-DCPE-induced Sphase arrest. Together, our data indicate that ERK activation correlated with the 2,3-DCPE-mediated induction of p21 expression and S-phase arrest. This finding may have implication for cancer therapy. Oncogene (2004Oncogene ( ) 23, 4984-4992. doi:10.1038 
Introduction
Cell cycle progression is tightly controlled by various cyclins, cyclin-dependent kinases (CDKs), CDK inhibitors, and certain tumor suppressor gene products, such as p53 and RB protein (Sherr, 1996) . Deregulation of the cell cycle is one of the critical events that drive cancer cells into uncontrolled proliferation (Evan and Vousden, 2001 ). Molecular changes, including the overexpression of cyclins and CDKs and the loss of CDK inhibitors and tumor-suppressor proteins resulting from gene mutations or epigenetic inactivation, are frequently detected in tumor cells (Sherr, 1996; Malumbres and Barbacid, 2001 ). Because of the important roles of cell cycle deregulation in tumorigenesis and tumor progression, molecules involved in cell cycle regulation also serve as potential targets for therapeutic intervention in cancers.
CDKs, the central players in cell cycle progression, are the ultimate targets of many anticancer investigations. Strategies explored to inhibit CDKs for cancer therapy include use of the small molecule CDK inhibitors (Senderowicz, 2000) ; gene therapy to restore the functions of CDK inhibitors, such as p21 (Eastham et al., 1995; Hall et al., 2000) , p16 (Schreiber et al., 1999) , and p27 (Katayose et al., 1997) ; modulating the expression of CDK inhibitors by small molecules (Lodygin et al., 2002) ; and suppressing the expression of cyclin D1 or cyclin E1 by antisense or small interfering RNA (siRNA) technologies (Kornmann et al., 1998) . Ectopic expression of CDK inhibitors by gene therapy was found to inhibit tumor growth in preclinical studies (Eastham et al., 1995; Katayose et al., 1997; Schreiber et al., 1999) . Meanwhile, certain small molecule modulators of CDKs are under clinical trials (Senderowicz, 2000) .
We recently found that a synthetic compound, 2 [[3-(2,3-dichlorophenoxy) propyl]amino]ethanol (2,3-DCPE), could induce apoptosis and down-regulate Bcl-XL expression in cancer cells (Wu et al., 2004) . Moreover, the forced overexpression of Bcl-XL blocked 2,3-DCPE-mediated apoptosis. Nevertheless, here we found that 2,3-DCPE also suppressed the growth of Bcl-XL-overexpressing cells. This finding promoted us to further investigate the effects of 2,3-DCPE on cell cycle progress. Our study showed that 2,3-DCPE could induce p21 expression and S-phase arrest in cancer cells correlated with ERK activation that is p53-and ATMdispensable.
Results

2,3-DCPE induces S-phase arrest
We have recently found that 2,3-DCPE could induce apoptosis in DLD-1 colon cancer cells and that enforced overexpression of Bcl-XL-attenuated 2,3-DCPE induced apoptosis (Wu et al., 2004) . Interestingly, growth of the Bcl-XL-overexpressing DLD-1/Bcl-XL cells was still suppressed by 2,3-DCPE at a high concentration (20 mM) and induction of apoptosis was observed at prolonged incubation (Figure 1a and b), suggesting that some functional changes might be involved. Induction of apoptosis by 2,3-DCPE in DLD-1/Bcl-XL cells was partially reversible after removal of the chemical by change of medium.
To test whether 2,3-DCPE induces cell cycle arrest, we treated DLD-1 cells with 2,3-DCPE or 2,3-DCEE, a molecule with a similar chemical structure but no effect on cell growth. Cells treated with DMSO were used as a control. Cell cycle analysis was performed 24 h after the treatment. The cells treated with DMSO or 2,3-DCEE had similar cell cycle profiles similar to those treated with PBS (data not shown). Nevertheless, treatment with 2,3-DCPE resulted in an apparent increase in the proportion of S-phase cells (Figure 1c) . A similar result was observed in DLD-1/Bcl-XL cells. Compared to treatment with DMSO, treatment with 2,3-DCPE resulted in an apparent increase in the proportion of S-phase cells (Figure 1d ). Because there was no difference between treatment with DMSO and 2,3-DCEE, DMSO was used as a control in subsequent experiments.
We then evaluated the effects of different doses of 2,3-DCPE. For this purpose, DLD-1 cells were treated with 2,3-DCPE at concentrations of 1-20 mM. Cells treated with DMSO were used as a control. Cell cycle analysis was performed 24 h after the treatment. S-phase arrest was induced by 2,3-DCPE at 5 mM or higher and was more effective at higher concentrations (data not shown).
To test the time course for this S-phase increase, we treated DLD-1 cells with 20-mM 2,3-DCPE. Cells were then harvested at various times after the treatment, and the cell cycle profile was determined by FACS analysis. S-phase arrest started after 12 h and peaked at 24-32 h after the treatment (Figure 2a) . In contrast, treatment with DMSO did not cause a significant change in cell cycle profiles at any of the time points tested (Figure 2a) . We also tested effects of 2,3-DCPE on the cell cycle profiles in normal fibroblasts. Our data showed 2,3-DCPE induced only mild increase of S-phase cells in the normal fibroblasts at early time points after treatment ( Figure 2b ). In comparison with DMSO, treatment with 20-mM 2,3-DCPE resulted in a mild increase of S-phase cells at 8-16 h after exposure. No significant difference was observed at 24 h and thereafter. 
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Upregulation of p21 by 2,3-DCPE
To identify the molecules involved in 2,3-DCPEmediated S-phase arrest, we tested the effect of 2,3-DCPE on the expression of cyclin-dependent kinase (CDK) inhibitors p21 and p27, which can lead to cell cycle arrest by inhibiting the activity of CDKs (Harper et al., 1993; Toyoshima and Hunter, 1994) . Western blot analysis showed that treatment with 20 mM 2,3-DCPE led to an apparent upregulation of p21 in DLD-1 cells that started at 4 h after treatment and strengthened over time ( Figure 3a) . Interestingly, the levels of p27 protein decreased slightly after treatment with 2,3-DCPE. The induction of p21 by 2,3-DCPE was dose-dependent ( Figure 3b ). To further evaluate the effect of 2,3-DCPE on p21 expression, we analysed p21 mRNA levels by real-time PCR. The level of p21 mRNA increased dramatically 1 h after treatment (see Figure 5c ). At 24 h after the treatment, the level of p21 mRNA in cells treated with 2,3-DCPE was 68-fold higher than that in the DMSO control, suggesting that 2,3-DCPE-induced p21 overexpression occurs at the transcriptional level.
Induction of p21 by 2,3-DCPE is p53-dispensable
The expression of p21 can be regulated by p53-dependent and -independent mechanisms (Gartel and Tyner, 1999) . Because p53 is mutant in the DLD-1 cell line, the upregulation of p21 by 2,3-DCPE is likely p53-independent. Analysis of p53 levels in DLD-1 cells after treatment with 20 mM 2,3-DCPE showed that p53 protein level did not change (Figure 4a ). To further test whether p53 is required for induction of p21 by 2,3-DCPE, we analysed p21 expression in p53-wild-type A549 cells and in p53-null H1299 cells after treatment with 2,3-DCPE. Although the background levels of p21 differ between these two cell lines, treatment with 2,3-DCPE resulted in induction of p21 in both. Induction of p21 was more dramatic in H1299 cells, which have a very low background level of p21. This result further demonstrated that the induction of p21 by 2,3-DCPE is p53-dispensable (Figure 4b ). Moreover, a comparison of p21 induction by 2,3-DCPE in DLD-1 and DLD-1/Bcl-XL also showed that the forced overexpression of Bcl-XL had no effect on 2,3-DCPE-induced p21 overexpression.
Induction of p21 by 2,3-DCPE correlates activation of ERK but not ATM
To delineate the mechanisms that underlie the 2,3-DCPE-mediated overexpression of p21, we tested the activation of some MAP kinases, including p38, ERK, and JNK, that are important regulators of p21 in other cell lines (Beier et al., 1999; Kim et al., 2002; Park et al., 2002) . Immunoblotting showed that treatment with 20-mM 2,3-DCPE led to ERK activation in two phases (Figure 5a ), The first phase of ERK activation began 2 h after 2,3-DCPE exposure and ended 8 h after exposure. The second phase began after 16 h. The mechanism of this biphasic change of ERK activation is unknown, however, a similar biphasic response of ERK has been reported after treatment with etoposide (Tang et al., 2002) . Nevertheless, 2,3-DCPE treatment did not result in the activation of p38 or JNK (data not shown). Together, these results suggest that ERK activation could be correlated with the 2,3-DCPE-mediated upregulation of p21.
To verify the correlation of ERK activation in 2,3-DCPE-mediated p21 upregulation, we tested the effects of two ERK inhibitors, PD98059 and U0126, that inhibit ERK activation by inhibiting the activity of the upstream kinase -MEK1/2 (Dudley et al., 1995; Favata et al., 1998) . Both PD98059 and U0126 could only (Figure 5b ) and effectively attenuated 2,3-DCPE-induced p21 overexpression (Figure 5d ). We also tested the effect of PD98059 on p21 mRNA levels after treatment with 2,3-DCPE. PD98059 partially blocked the 2,3-DCPEinduced upregulation of the p21 mRNA level 8 h after treatment (Figure 5c , Po0.05). These results indicate that ERK activation is correlated the 2,3-DCPEinduced upregulation of p21.
It has been reported that activation of ATM, a DNA damage sensor, led to the activation of ERK (Banin et al., 1998; Tang et al., 2002) . To test whether ATM activation is involved in the activation of ERK and the upregulation of p21 by 2,3-DCPE, we analyzed the effects of 2,3-DCPE in ATM-deficient cells. Induction of p21 expression and S-phase arrest and corresponding activation of ERK were observed in ATM-deficient cells after treatment with 2,3-DCPE (Figure 6a,b) , suggesting that ATM is dispensable for 2,3-DCPE induced ERK activation and S-phase arrest. Moreover, wortmannin and caffeine, the two agents that reportedly inhibit ATM, did not inhibit 2,3-DCPE-mediated ERK activation or p21 induction in cancer cells (data not shown).
ERK inhibitors block 2,3-DCPE-induced S-phase arrest but not apotosis
We then evaluated the effect of the ERK inhibitor PD98059 on 2,3-DCPE-mediated S-phase arrest and apoptosis. PD98059 partially blocked 2,3-DCPE-induced S-phase arrest (Figure 7 ). Treatment with the ERK inhibitor U0126 led to a similar result (data not shown). Together, these results suggest that the ERK pathway may be involved in 2,3-DCPE-induced S-phase arrest. Interestingly, PD98059 did not block 2,3-DCPE-induced apoptosis (Figure 7 ). Thus, it is possible that 2,3-DCPE-induced S-phase arrest and apoptosis involve separate pathways.
Discussion
Many stimuli, including chemicals and physical injuries, can induce cell arrest at different phases (Shapiro Induction of S-phase arrest and p21 activation H Zhu et al and Harper, 1999; Malumbres and Barbacid, 2001) . Agents that cause damage to DNA or spindle apparatus will cause either apoptosis or cell cycle arrest, which usually occurs at the G1/S or G2/M boundaries (Shapiro and Harper, 1999) . Moreover, certain taxanes and vinca alkaloids that cause G2/M arrest by damaging microtubules have proven clinically successful for cancer treatment (Toogood, 2002) . Consequently, cell cycle arrest at the G1/S and G2/M transitions has been intensively investigated in mammalian cells. In contrast, relatively little is known about mechanisms that control progress within the S-phase. Since replication of eukaryotic DNA is strictly controled so that each sequence is replicated once and only once during the S-phase, there must be mechanism for S-phase arrest in case exogenous damage triggers cells to neither go forward nor retreat to G1 status. In fact, S-phase arrest has been observed in mammalian cells with prolonged arrest at the G1/S boundary (Borel et al., 2002) ; Rb( þ / þ ) mouse embryo fibroblasts treated with cisplatin, etoposide or mitomycin (Knudsen et al., 2000) ; human melanocytes treated with thymidine dinucleotides (Pedeux et al., 1998) ; and human cancer SAOS-2 cells transduced with the p21 gene (Ogryzko et al., 1997) . Our observation that 2,3-DCPE-induced S-phase arrest and p21 overexpression is in agreement with a previous report that transduction of the p21 gene resulted in S-phase arrest (Ogryzko et al., 1997) . P21, an inhibitor of CDKs, directly inhibits CDK2, CDK3, CDK4, and CDK6 activity (Harper et al., 1993; Gartel and Tyner, 2002) . Overexpression of p21 usually leads to G1 or G2 arrest by inhibiting CDK activity. P21 can also directly inhibit DNA synthesis by binding to proliferating cell nuclear antigen (PCNA) (Waga et al., 1994; Chen et al., 1995) . The expression of p21 could be regulated at the transcriptional, post-transcriptional, or post-translational levels by p53-dependent and -independent mechanisms (el Deiry et al., 1993; Gartel and Tyner, 1999) . Any insults that damage DNA will lead to activation of ATM or ATR, which subsequently activate p53 and lead to p53-dependent induction of the p21 gene. Expression of p21 can also be induced by DNA-damaging agents via the ATM/ATR-ERK pathway. In this case, activated ATM/ATR activates ERK, which induces p21 expression in a p53-independent manner. Other studies also have shown that the ERK pathway increased p21 protein levels through phosphoration of protein . Our findings showed that p53 is dispensable for 2,3-DCPE-induced ERK activation and p21 expression. Blocking the activation of ERK partially blocked the induction of p21 expression and S-phase arrest, suggesting that ERK activation is correlated with 2,3-DCPE-mediated Sphase arrest and p21 induction. Moreover, ERK activation, p21 activation and S-phase arrest were observed in ATM-defective cells. Together, these results suggested that ATM is also dispensable for 2,3-DCPEmediated ERK activation and p21 induction. Thus, 2,3-DCPE-mediated induction of p21 may not arise from DNA damage and ATM activation as reported by others (Tang et al., 2002) .
ERK plays vital roles in cell growth and division and can be activated by a variety of extracellular stimuli (Johnson and Lapadat, 2002) , including various oncolytic agents and DNA-damaging agents (Chen et al., 1997; Bacus et al., 2001; Seidman et al., 2001; Tang et al., 2002) . Its activation can lead to activation of a variety of targets. For example, treatment of NIH3T3 cells with etoposide (VP16), an inhibitor of topoisomerase II, led to slight activation of ERK1, S-phase arrest, and induction of p21 independent of p53 (Chen et al., 1997) . Our finding with 2,3-DCPE is similar to this observation of etoposide (Chen et al., 1997) . Nevertheless, we showed that suppression of ERK activation attenuated 2,3-DCPE-mediated induction of p21 expression and S-phase arrest. Although ERK and p21 likely plays roles in 2,3-DCPE-mediated S-phase arrest, it is also possible that some other molecules that were not tested here are involved in 2,3-DCPE-mediated Sphase arrest. However, ERK activation may not correlate with early phase of 2,3-DCPE-mediated apoptosis, although prolonged arrest of S-phase may lead to apoptosis as well. Further investigation of the mechanisms of 2,3-DCPE-mediated S-phase arrest might shed light on molecular mechanisms of S-phase arrest.
Materials and methods
Cells and cell culture
Human colon cancer cell line DLD-1, its subclone DLD1/Bcl-XL, and human lung cancer cell lines A549 and H1299, and ATM defective fibroblast cell (AT22IJEpEBS7) were used in this study. The DLD1/Bcl-XL cells were derived from DLD-1 cells by stable transfection with the Bcl-XL gene as described previously (Zhang et al., 2002) and AT22IJEpEBS7 was originally constructed in the laboratory of Dr Yosef Shiloh (Ziv et al., 1997) . All cells were maintained in RPMI-1640 or Dulbecco's modified Eagle's medium plus 5% (v/v) heatinactivated fetal bovine serum, 1% glutamine, and 1% antibiotics. Cells were cultured at 371C in a humidified incubator containing 5% CO 2 . Chemicals 2,3-DCPE and 2[[3-(2,3-dichlorophenoxy)ethyl]amino] ethanol (2,3-DCEE) were purchased from ChemBridge (San Diego, CA, USA). They were dissolved in dimethyl sulfoxide (DMSO) at 20 mM as stock solution. ERK inhibitors PD98059 and U0126 were obtained from Calbiochem (La Jolla, CA, USA). DMSO, wortmannin, and caffeine were obtained from Sigma (St Louis, MO, USA).
Flow cytometry assay
Cells were trypsinized and washed with cold PBS once. The cells were then fixed with cold 70% ethanol overnight at 41C. At 30 min before the assay, propidium iodide staining was performed as described previously (Kagawa et al., 2001; Zhang et al., 2002) . For the apoptosis assay, the floating cells were included. The flow cytometry assay was performed in the Core Lab at The University of Texas MD, Anderson Cancer Center.
Western blot analysis
The cells were washed with cold PBS and subjected to lysis in Laemmli's lysis buffer. Equal amounts of lysate were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to Hybond enhanced chemiluminescence membranes (Amersham Corp., Arlington Heights, IL, USA). Membranes were then blocked with buffer containing 5% fat-free milk and phosphate-buffered saline containing 0.05% Tween-20 (PBST) for 1 h or overnight at 41C, washed three times with PBST, and incubated with primary antibodies for at least 1 h at room temperature or overnight at 41C. After being washed with PBST again, membranes were incubated with appropriate peroxidase-conjugated secondary antibodies and developed with an enhanced chemiluminescence detection kit (ECL kit; Amersham Bioscience, Buckinghamshire, England). Rabbit anti-human p27, ERK, phospho-ERK, p38, phospho-p38, JNK and phospho-JNK, and mouse anti-human p21 were purchased from Cell Signaling Technology (Beverly, MA, USA). Mouse anti-human p53 was obtained from Oncogene (San Diego, CA, USA). b-Actin was used as a loading control.
Real-time PCR
Real-time polymerase chain reaction (PCR) analysis was performed using the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Forster City, CA, USA) according to the manufacturer's protocol. Primers and a probe for p21 were designed using the built-in software in the Prism 7700 system and synthesized by Invitrogen (Frederick, MD, USA). The sequences for the two primers and the probe were 5 0 -CTGGAGACTCTCAGGGTCGAA-3 0 , 5 0 -GGCGTTTGGA GTGGTAGAAATC-3 0 , and 5 0 -ACGGCGGCAGACCAGC ATGAC-3 0 , respectively. A measure of 1 mg of total RNA from each sample was reverse-transcribed into cDNA by using random hexamers as reverse transcription primers (TaqMan Reverse Transcription Reagents, Applied Biosystems). Then a typical real-time PCR was performed as described previously (Zhang et al., 2002) . The human GAPDH gene was used as an internal control for normalization of the mRNA amount.
Statistical analysis
Differences between the treatment groups were assessed by an unpaired Student's t-test. Po0.05 was considered significant. ; ERK, extracellular signal-regulated kinase; ATM, ataxia telangiectasia-mutated; PBST, phosphate-buffered saline plus 0.05% Tween-20; PCR, polymerase chain reaction.
